Steward Partners Investment Advisory’s Aimmune Therapeutics AIMT Stock Holding History

Steward Partners Investment Advisory’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,000	Closed	-$50K	–	2911
2020 Q2	$50K	Hold	3,000	–	–	﹤0.01%	1417
2020 Q1	$43K	Sell	3,000 -2,000	-40%	-$51.1K	﹤0.01%	1323
2019 Q4	$167K	Sell	5,000 -2,102	-30%	-$58.8K	﹤0.01%	939
2019 Q3	$148K	Buy	7,102 +7,000	+6,863%	+$143K	0.01%	942
2019 Q2	$2K	Buy	+102	New	+$2.1K	﹤0.01%	2491
2018 Q4	–	Sell	-102	Closed	-$3K	–	2458
2018 Q3	$3K	Hold	102	–	–	﹤0.01%	2323
2018 Q2	$3K	Hold	102	–	–	﹤0.01%	2171
2018 Q1	$3K	Hold	102	–	–	﹤0.01%	1966
2017 Q4	$3K	Buy	+102	New	+$3.29K	﹤0.01%	1666

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Steward Partners Investment Advisory's AIMT Position: Q3 2020 in Review

Steward Partners Investment Advisory sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 3,000 shares — an estimated $50K sold.

Steward Partners Investment Advisory first reported a position in AIMT in Q4 2017 and held it in 9 quarters. The position peaked at $167K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Steward Partners Investment Advisory reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Steward Partners Investment Advisory sold 3,000 Aimmune Therapeutics shares in Q3 2020, an estimated $50K.
Steward Partners Investment Advisory first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 9 quarters.
Steward Partners Investment Advisory's Aimmune Therapeutics position peaked at $167K in Q4 2019.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2020, filed 30 Oct 2020.